Recommended regimen for combined use of Adalimumab and other drugs

Adalimumab is a fully humanized monoclonal antibody targeting tumor necrosis factor α (TNF-α). It is widely used to treat a variety of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease and psoriasis. By neutralizing TNF-α, it inhibits the inflammatory response and slows down disease progression. Due to the complexity and individual differences of many autoimmune diseases, adalimumab is often used in combination with other drugs to increase efficacy, improve symptoms, and prolong remission. The following will introduce in detail the combination regimen of adalimumab and other drugs and related clinical applications.

1. Combination of adalimumab and traditional immunosuppressants

When treating autoimmune diseases such as rheumatoid arthritis (RA), adalimumab is often combined with traditional immunosuppressants such as methotrexate (Methotrexate,MTX), leflunomide (Leflunomide), and azathioprine (Azathioprine) are used in combination. Methotrexate is the basic drug for the treatment of RA and can inhibit the proliferation of inflammatory cells and the release of inflammatory mediators. Studies have shown that the combination of adalimumab and methotrexate can significantly improve the clinical remission rate, reduce the progression of joint damage, and reduce the risk of drug-resistant bodies that may occur during monotherapy. In addition, combined medication can also reduce the dosage of adalimumab, reducing costs and the risk of side effects. The specific plan usually uses adalimumab injected once every two weeks, and methotrexate taken orally or injected once a week. The efficacy monitoring needs to be combined with inflammatory indicators and clinical manifestations.

2. Combination of adalimumab and glucocorticoids

In periods of high disease activity or acute exacerbations, adalimumab is often used in combination with glucocorticoids (such as prednisone, methylprednisolone) to quickly control the inflammatory response. Glucocorticoids have potent anti-inflammatory and immunosuppressive effects and can quickly relieve symptoms such as joint swelling, pain and tissue damage. The combination program usually uses short-term glucocorticoid treatment, with the dosage gradually reduced during the period, to avoid side effects such as osteoporosis and hyperglycemia caused by long-term use. As a long-term maintenance treatment, adalimumab works in conjunction with glucocorticoids to stabilize immune regulation and reduce the risk of recurrence. In clinical practice, patients' blood sugar, blood pressure, and infection risk should be closely monitored, and the hormone dosage should be adjusted reasonably.

3. Combination of adalimumab and small molecule targeted drugs

In recent years, small molecule targeted drugs such as JAK inhibitors (tofacitinib, baricitinib) and phosphatidylinositol 3-kinase (PI3K) inhibitors have become new options for the treatment of autoimmune diseases. When treatment with a single biological agent or small molecule drug is ineffective for some patients, doctors may choose combination therapy based on individual circumstances. Although the combination of adalimumab and JAK inhibitors is still in the research stage, some clinical trials have evaluated its safety and efficacy. The potential advantage of combination therapy lies in multi-target inhibition, enhanced immunomodulatory effect, and overcoming the problem of single-drug resistance. However, we need to be alert to the risks of infection and tumors caused by excessive immunosuppression, so such programs must be carried out under the close supervision of professional doctors.

4. Adalimumab and non-steroidal anti-inflammatory drugs (NSAIDs) and other adjuvant treatments

Nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen are commonly used to relieve pain and inflammation. Adalimumab combined with NSAIDs can improve the quality of life of patients, especially when inflammation is not completely controlled. In addition, physical therapy, rehabilitation exercises and nutritional support are also important components of combined treatment. For patients with intestinal inflammation, adalimumab combined with immunomodulators (such as azathioprine, methotrexate) and maintenance nutritional support can significantly improve the treatment effect and reduce the need for surgery.

Adalimumab, as a mature biological agent, is widely used in the treatment of various autoimmune diseases. By combining it with traditional immunosuppressants, glucocorticoids, small molecule targeted drugs and non-steroidal anti-inflammatory drugs, it can achieve multi-target, all-round disease control, improve efficacy, extend the remission period, and improve patients' quality of life. Combination drug regimens need to be designed individually, and the dosage and regimen should be adjusted based on the patient's specific condition, previous treatment response, and tolerance to avoid excessive immunosuppression and related adverse reactions. Patients should closely cooperate with their doctors during use and regularly monitor relevant indicators to ensure safe and effective treatment. In the future, with the development of immunology and pharmacology, adalimumab's combination drug strategies will be more abundant and precise, bringing good news to more patients.

Reference materials:https://www.drugs.com/